Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

DAC vs No-DAC: Two Distinct Compounds

CJC-1295 exists in two functionally different forms, and the distinction matters significantly for protocol design. CJC-1295 with DAC includes a Drug Affinity Complex, a reactive lysine linker that covalently bonds to serum albumin after injection. This albumi

This comparison does not assign a generated winner or score.

  • CJC-1295 exists in two functionally different forms, and the distinction matters significantly for protocol design.
  • CJC-1295 with DAC includes a Drug Affinity Complex, a reactive lysine linker that covalently bonds to serum albumin after injection. This albumin binding shields the peptide from degradation and extends its effective half-life to 6 to 8 days. The result is a sustained, continuous elevation of GH signaling that requires only one to two injections per week. However, this continuous stimulation means GH release is more tonically elevated rather than sharply pulsatile.
  • CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF, retains the four stabilizing amino acid substitutions but omits the albumin-binding complex. Its half-life is approximately 30 minutes, meaning each injection produces a relatively brief amplification of the natural GH pulse before clearing. This shorter duration more closely mimics the body's endogenous pattern of intermittent GHRH signaling.
More references

Related material

Comparison

Ipamorelin vs GHRP-6

Both activate the GHS-R1a receptor, but their selectivity profiles diverge significantly. GHRP-6 produces robust GH release but also drives substantial increases in cortisol, prol…

View details →
Comparison

Ipamorelin vs GHRP-2

GHRP-2 sits between Ipamorelin and GHRP-6 in the selectivity spectrum. It produces a slightly stronger GH pulse than Ipamorelin but also elevates cortisol and prolactin to a modes…

View details →
Comparison

CJC-1295 vs Sermorelin

Both are GHRH analogs targeting the same receptor, but they differ meaningfully in pharmacokinetics. Sermorelin is essentially the unmodified GHRH(1-29) fragment with a half-life …

View details →
Comparison

CJC-1295 vs Tesamorelin

Tesamorelin is the only GHRH analog with current FDA approval (granted in 2010 for HIV-associated lipodystrophy). It uses an N-terminal trans-3-hexenoic acid modification for DPP-…

View details →